Final NICE no for BMS’ Opdivo in urothelial carcinoma

4th July 2018 Uncategorised 0

The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

More: Final NICE no for BMS’ Opdivo in urothelial carcinoma
Source: News